BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

BioNTech SENASDAQ: BNTX

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of €266.1M rose 421.8% year over year, ahead of the +122.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 115.8% from the prior quarter. Over 3 fiscal years it compounded at +43.9% a year.

Context

  • Depreciation & amortization amounted to 13.3% of revenue in FY2025, up 2.5 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +421.8% holds above the trailing-twelve-month pace of +122.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
€266.1M+115.8% QoQ
Last fiscal yearDec 2025
€367.69M+23.4% YoY
LTMJun 2026
€676.85M+122.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+421.8%——
1 year+23.4%——
3-year CAGR+43.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the cash flow

Latest · FY2025
367.69M EUR
Year-over-year change
+23.4%
4-year CAGR
+48.7%

Depreciation & Amortization vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +122.9% is the highest of 9, against a peer median of -4.8%.
  • Depreciation & amortization amounts to 25.6% of revenue for BNTX, versus a peer median of 3.1%.
BNTX Competitors
Depreciation & Amortization for BNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€676.85M EUR+122.9%+43.9%25.6%
INCYIncyte CorporationLTM Jun 2026$98.28M USD+8.6%+11.2%1.7%
GMABGenmab A/SLTM Jun 2026$44M USD—-41.9%1.1%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$33.47M USD-27.6%+30.8%8.8%
IBRXImmunityBio, Inc.LTM Sep 2026$16.54M USD+4.6%-5.3%9.1%
IMTXImmatics N.V.LTM Mar 2026€12.05M EUR-2.4%+19.6%32.3%
XNCRXencor, Inc.LTM Jun 2026$10.17M USD-10.7%+6.1%9.7%
MGNXMacroGenics, Inc.LTM Mar 2026$6.94M USD-7.1%-22.5%4.4%
IMCRImmunocore Holdings plcLTM Mar 2026$3.36M USD-17.0%-23.1%0.9%
TGTXTG Therapeutics, Inc.LTM Sep 2026$316K USD+32.2%-22.0%0.0%
CGENCompugen Ltd.LTM Dec 2025$0 USD—-0.5%0.0%
Peer median (excluding BNTX) —-4.8%-2.9%3.1%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.05B12.95B1.19B(677.7M)(1.09B)
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
Deferred Income Tax000070.98M
Stock-Based Compensation93.9M108.6M51.4M100.9M0
Change in Working Capital(10.73B)4.52B5.57B1.22B516.57M
Accounts Receivables(11.81B)4.37B5.37B387.7M1.04B
Inventory(438.4M)62.9M81.9M74.5M170.88M
Accounts Payables1.52B85.7M118.9M758.4M(695.23M)
Other Working Capital00000
Other Non-Cash Items(3.6B)(4.13B)(1.62B)(734.1M)574.01M
Operating Cash Flow889.7M13.58B5.37B207.7M438M
Capital Expenditures(154M)(363.3M)(705.5M)(452.3M)(168.19M)
Acquisitions (Net)(20.8M)0(336.9M)0183.27M
Purchases of Investments(394.7M)(47.8M)(6.98B)(12.37B)(10.97B)
Sales of Investments0375.2M1.19B10.74B9.14B
Other Investing Activities(23.1M)(33.5M)(576.59M)(164.6M)0
Investing Cash Flow(566.1M)(35.3M)(6.95B)(2.08B)(2.37B)
Debt Repayment(66.7M)(59.1M)(40.1M)(45.9M)(10.85M)
Common Stock Issued160.9M110.5M000
Common Stock Repurchased0(986.4M)(738.5M)00
Dividends Paid0(484.3M)000
Other Financing Activities0000(39.96M)
Financing Cash Flow94.2M(1.42B)(778.6M)(45.9M)(50.81M)
Effect of Forex Changes64.7M60.1M150.3M14.8M1.05B
Net Change in Cash482.5M12.18B(2.21B)(1.9B)(931.17M)
Free Cash Flow735.7M13.21B4.67B(244.6M)269.81M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.